vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

BTIG maintained a Buy rating on vTv Therapeutics (VTX) with a $57 price target, implying 101.9% upside from the Oct 13 close. The company is advancing its clinical pipeline, including cadisegliatin, which has FDA Breakthrough Therapy Designation, and plans Phase 3 and Phase 2a trials for T1D treatment.

vTv Therapeutics (VTVT) shares rose 6.4% premarket after the FDA granted orphan drug designation to HPPD, its treatment for sickle cell disease. The company's CEO highlighted the designation's role in advancing partnering discussions. vTv also focuses on cadisegliatin, a late-stage type 1 diabetes program with FDA Breakthrough Therapy designation.

The FDA granted orphan drug status to vTv Therapeutics' (VTVT) sickle cell treatment HPPD. Preclinical studies showed it increased fetal hemoglobin and reduced red blood cell sickling, with effects comparable to or better than hydroxy urea, according to the company.

vTv Therapeutics (VTVT) announced FDA Orphan Drug Designation for HPPD, an oral treatment for sickle cell disease. The company's primary focus remains a Phase 3 diabetes drug. The designation is an early regulatory milestone.

vTv Therapeutics (VTVT) announced FDA Orphan Drug Designation for HPPD, its investigational treatment for sickle cell disease. HPPD showed promise in preclinical studies, increasing fetal hemoglobin and reducing oxidative stress. The company is also developing cadisegliatin for type 1 diabetes, which has Breakthrough Therapy designation.

vTv Therapeutics (VTVT) completed enrollment of 166 patients in its Phase 3 CATT1 study for cadisegliatin, an oral glucokinase activator for type 1 diabetes. The study, with FDA Breakthrough Therapy designation, will assess hypoglycemic events and other endpoints. Results are expected in mid-2027. The drug aims to reduce hypoglycemia risk in type 1 diabetes patients.